Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Neoplasms 4Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Lymphoproliferative Disorders 2Glioma 2Melanoma 1Locally Advanced Thyroid Gland Carcinoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

Magnetic Resonance Spectroscopy 19Temozolomide 16Radiotherapy 10Specimen Handling 7Blood Specimen Collection 7Radiation 6Bevacizumab 5Nivolumab 4Cyclophosphamide 4Biopsy 4vorasidenib 3trametinib 3pembrolizumab 3olaparib 3fludarabine 3dabrafenib 3Watchful Waiting 3Surgical Procedures, Operative 3Magnetic Resonance Imaging 3Drug Therapy 3olutasidenib 2lutetium Lu 177 dotatate 2fluorodopa F 18 2fluciclovine F-18 2entrectinib 2contrast agent BR1 2Restraint, Physical 2Radiosurgery 2Microdialysis 2Flucytosine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Glioma × entrectinib × Clear all
NCT06528691 2026-05-13

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

St. Jude Children's Research Hospital

Phase 2 Recruiting
52 enrolled
CNS

Glioma, Central Nervous System Neoplasms

NCT05770544 2025-11-24

DETERMINE

Cancer Research UK

Phase 2/3 Recruiting
30 enrolled
CNSDermatologicLymphoidOther hematologic neoplasm

Brain Neoplasms, Glioma, Lymphoproliferative Disorders, Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡